Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BGB-11417 + Dexamethasone + Pomalidomide |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BGB-11417 | BGB 11417|BGB11417|Sonrotoclax | BCL2 inhibitor 29 | BGB-11417 selectively inhibits Bcl2, which potentially leads to decreased tumor cell proliferation and inhibition of tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 3077). | |
| Dexamethasone | Adexone | Desametasone | ||
| Pomalidomide | Pomalyst | CC-4047 | Pomalyst (pomalidomide) is a thalidomide derivative that inhibits angiogenesis and modulates immune response, potentially lead to antitumor activity (PMID: 30069630). Pomalyst (pomalidomide) is FDA approved for use in patients with Kaposi's sarcoma who failed HAART or are HIV-negative, and in combination with dexamethasone in patients with multiple myeloma who had 2 or more prior therapies (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04973605 | Phase Ib/II | BGB-11417 BGB-11417 + Carfilzomib + Dexamethasone BGB-11417 + Dexamethasone BGB-11417 + Dexamethasone + Pomalidomide BGB-11417 + Daratumumab + Dexamethasone | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | Recruiting | USA | ITA | ISR | GRC | GBR | ESP | DEU | CAN | BRA | AUS | 3 |